4.81 USD
-0.02 (-0.41%)
5.08 USD
+0.27 (+5.61%)
Taking everything into account, ABEO scores 2 out of 10 in our fundamental rating. ABEO was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of ABEO have multiple concerns. While showing a medium growth rate, ABEO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- ABEO had negative earnings in the past year.
- ABEO had a negative operating cash flow in the past year.
- In the past 5 years ABEO always reported negative net income.
- ABEO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ABEO has a Return On Assets of 35.63%. This is amongst the best in the industry. ABEO outperforms 98.67% of its industry peers.
- ABEO has a Return On Equity of 48.09%. This is amongst the best in the industry. ABEO outperforms 98.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 35.63% | ||
| ROE | 48.09% | ||
| ROIC | N/A |
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 20587.50%, ABEO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
- The Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 20587.5% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ABEO has been increased compared to 1 year ago.
- The number of shares outstanding for ABEO has been increased compared to 5 years ago.
- Compared to 1 year ago, ABEO has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -1.93, we must say that ABEO is in the distress zone and has some risk of bankruptcy.
- ABEO has a Altman-Z score (-1.93) which is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.06 indicates that ABEO is not too dependend on debt financing.
- The Debt to Equity ratio of ABEO (0.06) is worse than 60.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.93 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- ABEO has a Current Ratio of 9.74. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
- ABEO's Current ratio of 9.74 is fine compared to the rest of the industry. ABEO outperforms 79.81% of its industry peers.
- ABEO has a Quick Ratio of 9.53. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of ABEO (9.53) is better than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.74 | ||
| Quick Ratio | 9.53 |
3. Growth
3.1 Past
- ABEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.38%, which is quite impressive.
- The Revenue for ABEO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, ABEO will show a very strong growth in Earnings Per Share. The EPS will grow by 28.39% on average per year.
- Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 412.56% on average per year.
EPS Next Y172.22%
EPS Next 2Y40.32%
EPS Next 3Y37.35%
EPS Next 5Y28.39%
Revenue Next Year6533.33%
Revenue Next 2Y3247.96%
Revenue Next 3Y1168.37%
Revenue Next 5Y412.56%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABEO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ABEO's earnings are expected to grow with 37.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.32%
EPS Next 3Y37.35%
5. Dividend
5.1 Amount
- ABEO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ABEONA THERAPEUTICS INC / ABEO FAQ
Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to ABEO.
Can you provide the valuation status for ABEONA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.
How profitable is ABEONA THERAPEUTICS INC (ABEO) stock?
ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.